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Abstract 
 
Paraoxonase (PON1) has been implicated to have a cardioprotective role, due to its physical 
attachment with high-density lipoprotein. PON1192QR is a variation of the PON1 gene, the R 
allele being a risk factor for cardiovascular disease. Kinetic studies resulting in a plot of 
paraoxon versus diazoxon hydrolysis rates may be used to accurately predict PON1192 geno-
type. In this study, paraoxonase and diazoxonase activities in plasma were measured spec-
trophotometrically using plasma while PCR-based PON1192 genotyping was performed us-
ing polymerase chain reaction followed by restriction digestion. The two-substrate assay-
derived genotypes were cross-referred with those determined by PCR-based genotyping. 
When results did not concur, sequencing of the 99-bp region spanning codon 192 of PON1 
was performed to verify the genotype. Concordant samples with high or low activities were 
sequenced for comparison. In addition, the rare PON1194WX polymorphism was examined as 
a source of discordance. The frequency of the PON1192Q allele in a Malaysian population 
comprising three ethnic groups (Malays, Chinese and Indians) was estimated to be 0.46, and 
that of the PON1192R allele, 0.54. Discordance between the genotype and phenotype was ob-
served for two samples. One of the two subjects genotyped as PON1192QR and phenotyped as 
PON1192QQ. The sample showed low paraoxonase and diazoxonase activities. Sequencing 
confirmed that the genotype was PON1192QR. The other subject was genotyped as PON1192RR 
but phenotyped as PON1192QR. Sequencing showed that the genotype was in fact PON1192RR, 
with the subject showing relative high activities. The PON1194WX mutation was not detected 
in the sequenced samples and was not the source for discordance. 
 
Introduction 
 
Paraoxonase1 (PON1) is an esterase belonging to a family 
of proteins that includes PON2 and PON3 [1]. The genes 
coding for the PON family are located on human chromo-
some 7 (q21.22). PON1 has two exonic amino acid poly-
morphisms, one at position 55 (methionine/leucine; M/L) 
and another at position 192 (arginine/glutamine; R/Q). 
PON1 is associated with high-density lipoprotein (HDL) 
particles, thus linked to the prevention of oxidative dam-
age to low-density lipoprotein (LDL) particles. The pro-
tective effect of HDL has been implicated in arresting the 
development of coronary heart disease (CHD), as well as 
other vascular complications of diabetes [2]. Several stud-
ies describe the PON1192R allele as a significant risk factor 
for heart disease although a meta-analysis of 43 such 
studies have shown a weak association whereby the esti-
mated relative risk of PON1192R for coronary heart disease 
was 1.12 [3]. Thus genotyping the diabetic individuals for 
both the PON1 192QR and 55LM polymorphisms updates 
available data and would be useful in identifying those 
individuals at the highest risk of developing complica-
tions. The characteristics of PON1192QQ, -QR and -RR geno-
types are such that the plasma activity differs towards the 
substrates paraoxon and diazoxon. The PON1192Q poly-
morphism causes a ten-fold decrease in paraoxonase ac-
tivity. The PON1192R mutation possibly reshapes the ac-
tive site thereby improving the positioning of paraoxon 
[4]. In addition, hydrophobicity is common to most of 
PON1’s effective substrates, probably due to the hydro-
phobicity and depth of PON1’s active site. Therefore, the 
poor and effective substrates bind at the active site with 
similar affinity, except that the mode of binding differs; 
the poor substrates would be inadequately positioned, 
resulting in a lower activity. 
 
Material and Methods 
 
Outpatients who attended the Diabetic Clinic, University 
of Malaya Medical Centre, Kuala Lumpur, and healthy 
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volunteers residing in Selangor and Kuala Lumpur were 
screened for the study. This study was approved by the 
University of Malaya Medical Ethics Committee (MEC) 
and informed consent was obtained from all subjects.  
 
Table 1:  Characteristics of subjects with discordant PON1192 genotypes in comparison  
with selectedConcordant samples 
 
 
Group 
 
Discordant 
 
Discordant 
 
Low 
POase activity 
 
Low DZOase 
activity 
 
High 
POase 
activity 
 
High 
DZOase 
activity 
 
PON1192 genotype QR RR QR RR RR QQ 
PON1192 phenotype QQ QR QR RR RR QQ 
PON1192 genotype (se-
quenced) 
QR RR QR RR RR QQ 
POase activity (U/L) 143 599 107 765 1049 315 
DZOase activity (U/L) 10030 14037 3819 6770 4985 27571 
PON155 genotype LL LL LL LL LL LL 
Age (years) 29 43 52 58 53 45 
Sex Male Male Male Female Female Female 
Ethnicity Malay Malay Chinese Malay Malay Malay 
Diabetes/Cardiovascular 
complications 
None None Diabetic/ 
Hypertensive 
Diabetic/ 
Hypertensive 
None None 
HDL-C (mmol/L  ) 1.16 0.93 0.71 0.82 1.63 1.10 
 
 
Demographic characteristics of each subject were re-
corded. All subjects were screened for the variations in 
the PON1 gene, including unmatched cases or controls. 
Venous blood samples were obtained by a trained phle-
botomist under sterile conditions from subjects. Genomic 
DNA was extracted from whole EDTA blood using a 
Gene All Blood DNA Purification kit (General Biosys-
tem, Seoul, South Korea). PON1 genotypes were deter-
mined by the PCR-based methods [5]. To assess poly-
morphism at position 192, the sense primer (5’ TAT TGT 
TGC TGT GGG ACC TGA G 3’) and the antisense 
primer (5’ CAC GCT AAA CCC AAA TAC ATC TC 3’) 
which encompass the codon 192 of the human PON1 
gene were used. For the polymorphism at position 55, the 
sense primer (5’ AGA GGA TTC AGT CTT TGA GGA 
AA 3’) and the antisense primer (5’ CTG CCA GTC CTA 
GAA AAC GTT 3’) were used. PCR reactions were car-
ried out using a Hybaid Omnigene thermal cycler (Hy-
baid, Middlesex, UK). The hot-start PCR reaction mixture 
for the PON1-192 polymorphism contained 100 ng of 
DNA template, 0.5 μM of each primer, 1.5 mM MgCl2, 
200 μM of each dNTP and 1 unit of Taq DNA poly-
merase and hot-start antibody mixture (Biotherm PCR kit, 
Genecraft, Germany). The reaction mixture was denatured 
for 3 min at 93oC, followed by 35 cycles of 1 min of de-
naturation at 93oC, 30 s of annealing at 61oC and 1 min of 
extension at 72oC. The final extension was 7 min at 72oC. 
The resulting 99 bp PCR product was then digested with 
5 units of AlwI restriction endonuclease (New England 
Biolabs, Cambridge, MA, USA) overnight at 37oC, fol-
lowed by size fractionation on 4% agarose gels with 10 μl  
 
matched undigested and digested samples loaded alter-
nately into sample wells. Visualization was carried out 
with ethidium bromide staining. The R genotype (argin-
ine) contains a unique AlwI restriction site which results  
in products of 63 and 36 bp, whereas the Q genotype 
(glutamine) is not cut.  
 
For the PON1-55 polymorphism, the PCR reaction mix-
ture contained 100 ng of DNA template, 0.5 μM of each 
primer, 1.5 mM MgCl2, 200 μM of each dNTP and 1 unit 
of Taq DNA polymerase (Biotherm). After denaturation 
for 5 min at 94oC, the reaction mixture was subjected to 
35 cycles of 30 sec of denaturation at 94oC, 30 sec of an-
nealing at 61oC and 30 sec of extension at 72oC. The final 
extension time was 7 min at 72oC. The 386 bp PCR prod-
uct was digested with NlaIII (New England Biolabs) in 
the presence of BSA overnight at 37oC. Digested products 
were separated in 3% agarose gels. The L genotype (leu-
cine) does not contain an NlaIII site, whereas the M geno-
type (methionine) contains an NlaIII site, giving rise to 
products of 296 and 90 bp [5]. For two-substrate assays, 
paraoxonase and diazoxonase activities of corresponding 
heparinised plasma samples were measured spectropho-
tometrically (Varian Cary 50, Varian Inc. Scientific, Aus-
tralia). A two-dimensional plot of diazoxon versus 
paraoxon hydrolysis rates allowed simultaneous PON1-
192 genotyping and activity phenotyping of each individ-
ual [6]. The genotypes obtained from both methods were 
compared. Sequencing was performed to validate geno-
types in cases of discordance. Subjects with low activities 
for their PON1192 genotype were chosen for sequencing 
Discordance in paraoxonase 1 polymorphism                                                                                                                    35 
 
purposes as follows: PON1192QQ subjects with dia-
zoxonase activities under 5000 U/L, and PON1192QR and –
RR subjects with paraoxonase activities less than 200 U/L 
and 400 U/L, respectively. Reference to figure 1 shows 
that paraoxonase and diazoxonase activities are low for 
the subjects identified. The 99-bp PCR product was puri-
fied by using a kit (MinElute, Qiagen, The Netherlands) 
and sequenced on an ABI 3730 DNA Analyzer (Applied 
Biosystem, California, USA). The sequenced products 
were compared using the nucleotide blast program against 
a nucleotide sequence database with reference to Genbank 
Accession #AF539592 [7]. The presence of the 
PON1194WX genotype was also examined based on the 
results from sequencing. 
 
Results and Discussion 
 
Examination of demographic characteristics showed that a 
greater proportion (60%) of the study population con-
sisted of women. Malays constituted 47% of the study 
population, followed by Indians (33%) and Chinese 
(20%). The pooled age range was 17-97 years, with the  
mean age being 52 ± 13.5 years old. The subjects who 
were diabetic made up 52 % while the remaining 48 % 
were the non-diabetic controls. The observed frequencies 
of L, M, Q and R alleles in the pooled population were 
0.912, 0.088, 0.459 and 0.541, respectively. Discordance 
between the genotype and phenotype was observed for 
two samples, 29- and 43-year-old, both healthy males. 
The 29-year- old subject was genotyped as PON1192QR 
and activity phenotyped as PON1192QQ. The sample had 
low paraoxonase and diazoxonase activities (Table 1). 
DNA sequencing confirmed that the genotype was 
PON1192QR. This subject had PON1 activity (<200 U/L) in 
the lowest tertile within its genotype group (Fig. 1). This 
low activity is consistent with the inactive allele hypothe-
sis whereby the PON1192R allele is predicted to be inactive 
in this heterozygote. 
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Figure 1: Determination of the functional genomics of plasma PON1 using the 
PON1192 bivariate phenotype versus genotype plot. The PON1192QQ, -QR and -RR 
genotypes are shown as closed circles, triangles and diamonds, respectively. The 
two discordant subjects are indicated by open circles. 
 
The 43-year-old subject was genotyped as PON1192RR but 
phenotyped as PON1192QR. Sequencing showed that the 
genotype was PON1192RR, with the subject showing relat-
ive high activities. For both samples, the presence of the 
rare PON1trp194stop polymorphism (PON1WX) which coded 
for the stop codon was assessed. All the selected samples 
were confirmed to be of the common PON1194WW geno-
type. This subject showed comparatively high  paraoxo-
nase and diazoxonase activities. As the placement of acti-
vity  on  the  plot reflects the differential expression of the  
PON1192Q and PON1192R alleles, PON1192 homozygotes is 
 
genotype. In this case, the subject not only displayed dis-
crepant genotypes despite being homozygous, it also dis-
played high activities.  
 
Repeated genotyping and phenotyping were performed to 
eliminate the possibility of error. In fact, other reports 
have noted the incidence of error when the salt-
stimulation assay was used. Eckerson et al. [8] noted that 
one of the two individuals misclassified had low paraoxo-
nase activity.  The percentage of error was less than 1%. 
Browne et al. [9] reported a slightly higher error or ana-
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lytical imprecision of 1.0-3.0%. These errors were re-
solved when the genotypes were compared using various 
techniques. The rare PON1 protein truncation mutation 
PON1trp194stop may result in diminished PON1 activity. 
This alteration has been associated with the PON1192R 
allele (Jarvik et al., 2003). In the present study, all sub-
jects sequenced for the mutation carried the PON1194WW 
genotype which was not the stop codon, thereby ruling 
out the effect of the stop codon on the loss of function of 
the particular allele. This is to be expected as the allele 
frequency of such a mutation occurring is relatively low 
at 1/458 PON1192R alleles in the population studied by 
Jarvik et al. (2003). 
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